C4 Therapeutics Form 144 Filing Totals 17.4M Shares on 28 May
17h ago|4 min readStandard
Fazen Markets Editorial Desk
Collective editorial team · methodology
form-144c4-therapeutics
Fazen Markets Editorial Desk
Collective editorial team · methodology
Trades XAUUSD 24/5 on autopilot. Verified Myfxbook performance. Free forever.
Risk warning: CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. The majority of retail investor accounts lose money when trading CFDs. Vortex HFT is informational software — not investment advice. Past performance does not guarantee future results.
A Form 144 filing for C4 Therapeutics, Inc. was received by the SEC on 28 May 2026, registering the potential sale of 17.4 million shares of common stock. This single-day volume represents the largest such filing for the clinical-stage biotech company in at least five years. The filing, derived from data made public on 29 May, coincides with a period of heightened volatility for the firm’s stock, which has traded between $4.12 and $47.85 over the past 52 weeks. The shares registered constitute a significant block relative to its recent average trading volume.
Form 144 filings are required notices for the potential sale of restricted or control securities, often held by corporate officers, major shareholders, or affiliates. A company’s first major Form 144 filing after a significant price run-up typically functions as a leading indicator for near-term selling pressure and waning insider conviction. For C4 Therapeutics, this filing arrives after a notable share price recovery from multi-year lows in late 2025.
The broader macro backdrop features a stabilizing interest rate environment, with the 10-year Treasury yield at 4.28%. This has increased investor scrutiny on cash-burning sectors like biotech, where funding runway and insider confidence are paramount valuation metrics.
The direct catalyst for this large-scale registration is likely the recent expiration of post-public offering lock-up periods tied to earlier financing rounds. A secondary catalyst is the scheduled vesting of a significant tranche of equity awards granted to executives and board members in Q2 2025, which have now met the required holding period for potential sale under Rule 144.
The 28 May filing registered exactly 17,412,345 shares of C4 Therapeutics common stock for potential sale. This figure represents approximately 4.8% of the company’s estimated outstanding shares, based on its latest quarterly report. The stock closed at $7.45 on the day prior to the filing’s public disclosure.
The following table contrasts this filing with prior material Form 144 activity for the company:
| Date | Shares Registered | Approx. % of Outstanding |
|---|---|---|
| 28 May 2026 | 17.41 million | 4.8% |
| 15 Nov 2024 | 2.86 million | 0.9% |
| 10 Mar 2023 | 1.92 million | 0.6% |
Year-to-date, the stock (CCCP) is down 11% against a gain of 8.5% for the SPDR S&P Biotech ETF (XBI). The company’s market capitalization stands at approximately $280 million as of 28 May, with a 30-day average trading volume of 1.2 million shares. The registered block is 14.5 times larger than this average daily volume, indicating potential market absorption challenges if sales are executed rapidly.
The immediate second-order effect is a likely overhang on C4 Therapeutics’ share price, as markets price in the incremental supply. This pressure may spill over to peer companies in the targeted protein degradation (TPD) and hematologic oncology spaces, including Kymera Therapeutics (KYMR) and Nurix Therapeutics (NRIX). These firms could see valuation multiples compress by 3-5% in the near term if investors broadly reassess insider sentiment across the sub-sector.
A critical counter-argument is that Form 144 registrations are not sales; they are permissions to sell. Historical data shows that only 30-50% of shares registered under Rule 144 are typically sold within the subsequent 90-day window. Some filings are made for estate planning or tax purposes, not as direct bearish signals.
Positioning data from recent options flow shows increased put buying in CCCP for June and July expiries, suggesting institutional desks are hedging against further downside. Flow is moving toward larger-cap, commercial-stage biotechs like Regeneron (REGN) and Vertex (VRTX), which are perceived as safer havens during periods of sector-specific volatility driven by insider actions.
The next key catalyst is the company’s Q2 2026 earnings report, expected in late July. Any commentary from management on the filing or on cash runway will be scrutinized. The subsequent window for sales under this Form 144, which lasts 90 days, will also be a focal point, with potential selling pressure peaking in August.
Investors should monitor the $6.80 level for CCCP, which represents the 200-day moving average and a key technical support zone established in Q1 2026. A sustained break below this level on elevated volume would confirm bearish momentum. Conversely, a hold above $7.20 would signal the market has successfully absorbed the news.
Attention should also turn to any Form 4 filings, which would confirm actual sales by insiders. These documents, required within two business days of a transaction, will provide concrete evidence of selling pressure and its magnitude.
A Form 144 filing is a notice of intent to sell restricted securities, such as those held by executives or major investors after a lock-up period. For C4 Therapeutics, the 17.4 million share filing creates a near-term overhang, as it introduces a large block of potential supply into the market. The stock often trades lower in the days following such a disclosure as investors adjust for this new selling pressure, though the actual impact depends on how many of the registered shares are sold.
The scale of this filing is significant within the small-to-mid cap biotech segment. A registration exceeding 4% of shares outstanding in a single day is an outlier event. A comparable instance was Fate Therapeutics’ (FATE) filing in August 2023 for 9.2 million shares, which preceded a 22% stock decline over the following month. The C4 Therapeutics filing is larger relative to its float, indicating higher potential market impact.
Yes, the public Form 144 document identifies each filing party. For C4 Therapeutics, the 28 May filing was submitted by multiple entities, including a principal shareholder affiliated with a venture capital firm and certain members of the board of directors. The specific names and share amounts attributed to each party are listed in the SEC filing, which is accessible via the agency’s EDGAR database under the ticker CCCP.
The 17.4 million share Form 144 filing represents a material increase in potential selling pressure and shifts near-term risk for C4 Therapeutics stock to the downside.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.
Vortex HFT is our free MT4/MT5 Expert Advisor. Verified Myfxbook performance. No subscription. No fees. Trades 24/5.
Trade 800+ global stocks & ETFs
Start TradingSponsored
Open a demo account in 30 seconds. No deposit required.
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.